Optimizing Treatment on Idiopathic Inflammatory Myopathies

Last updated: December 4, 2024
Sponsor: University of Sao Paulo
Overall Status: Active - Recruiting

Phase

N/A

Condition

Idiopathic Inflammatory Myopathies

Myositis

Treatment

Intravenous Infusion

Clinical Study ID

NCT03092180
MYO-HCFMUSP-01
  • Ages > 18
  • All Genders

Study Summary

As a T2T, our patients with idiopathic inflammatory myopathies will receive pulse therapies with methyprednisolone and/or human intravenous immunoglobulin, or only methyprednisolone at disease onset.

This scheme is an internal routine protocol of our Service.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Idiopathic inflammatory myopathies

Exclusion

Exclusion Criteria:

  • Inclusion body myositis, muscular dystrophies, neoplasia-associated myopathies,overlapped myopathies, others myopathies

Study Design

Total Participants: 60
Treatment Group(s): 1
Primary Treatment: Intravenous Infusion
Phase:
Study Start date:
January 01, 2005
Estimated Completion Date:
December 04, 2024

Study Description

To compare two groups of patients as described in Brief Summary.

Connect with a study center

  • Samuel Katsuyuki Shinjo

    Sao Paulo, 01246903
    Brazil

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.